Nanobodies Market, by Product Type (Mono-specific and Multi-specific), by Indication (Acquired Thrombotic Thrombocytopenic Purpura (TTP), Respiratory Syncytial Virus Infection, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Oncology, Immune‐mediated Inflammatory Diseases (IMID), Psoriasis, Chronic Kidney Diseases, Bone Disorders, and Others), by Distribution Channel and by Geography - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

  • To Be Published : Oct 2018 |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Nanobodies are considered to be one of the best technology in the fields of research, diagnostics and therapy especially in cancer research. These technology was developed from antigen binding fragments, originating from Camelid heavy-chain antibodies. These molecules do not have light chains, which is an essential part of antibody found in humans. Based on the above finding, nanobodies molecule containing single-domain only were developed, and these molecules contain functional and structural properties similar to heavy chain antibodies. These molecules have several advantages as compared to the conventional antibodies such as small-size, nano to picomolar affinities, and multiple route of administration. Ablynx, which is acquired by Sanofi S.A., is one of the leading company in this market.

Nanobodies Market Drivers

Currently, no products are available in the market, but there are multiple products in the pipeline including few in very late stage of clinical trials. For instance, marketing authorization application for Caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) has been submitted to European Medicine Agency (EMA) in February 2017. The product, Caplacizumab, is expected to be launched in Europe in 2018. Moreover, the company, Ablynx, is expected to file for biologic license agreement to the U.S. Food and Drug Administration (FDA) in 2018, and is expected to launch this product in U.S. in 2019. Both, Europe and U.S. are the key markets for any biologics including monoclonal antibodies and are expected to be the high revenue generating market for nanobodies. Hence, approval by regulatory bodies in Europe and U.S. to Caplacizumab in very near future (i.e. 2018, 2019) is expected to drive the growth of global nanobodies market. As per the company, Ablynx, estimates the product has potential to generate more than US$ 1 Bn. Furthermore, there are multiple products in early stage of clinical development i.e. preclinical, phase 0, and phase 1. Ablynx alone had 8 products in clinical development phase (i.e. phase 0 to phase 3) and overall 45 products in pipeline as of March 2017.

Lucrative potential in the market has motivated leading biotechnology companies such as C.H. Boehringer Sohn AG & Ko. KG, MERCK KGaA, Merck & Co., Inc., AbbVie, Inc., Novo Nordisk A/S and Sanofi S.A. to collaborate or enter into a partnership agreement with the nanobodies manufacturer, Ablynx. In July 2017, Ablynx entered into a research collaboration and licensing agreement with Sanofi S.A. for the treatment of various immune-mediated inflammatory diseases. As per the agreement, Sanofi S.A. will get access to Ablynx’s scientists and technology platforms, and also, to certain drugs in pipeline. Furthermore, in 2015, Ablynx and Merck & Co., Inc. expanded their collaboration agreement focused on immuno-oncology. In January 2018, Sanofi S.A. made an offer to acquire Ablynx, and the offer was unanimously recommended by Ablynx board.

Nanobodies Market Regional Analysis

Europe is expected to hold dominant position in global nanobodies market, owing to the first mover advantage. Marketing authorization application (MMA) to EMA for Caplacizumab was filed by Ablynx in February 2017, and the company expects to get approval in 2018. If approved, Europe will be the only market to have nanobodies commercially available. However, North America is expected to show rapid growth in this market, as the company is planning to file for biologic license agreement for the same product to U.S. FDA in 2018, and expects to get approval from FDA by 2019. Once approved in U.S., the company may plan to reap the maximum benefit out of it. Furthermore, the drug, Caplacizumab, is expected to have better efficiency compared to both the available treatment (i.e. plasma exchange therapy and immunosuppressant) for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). In Asia Pacific, Japan may take the lead as multiple products such as Caplacizumab, Vobarilizumab, and ALX- 0171 has successfully gone through initial phase of clinical development.

Nanobodies Market Restraint

Presently, there are no products in market, and more than two-third products in very early phase of development, and these products have to go through various phases of clinical development. Failure in clinical trials for these products or slow approval by the regulatory bodies in the market may prove to be vital restraint in this market.

Nanobodies Market Key Players

Ablynx (now part of Sanofi S. A.) is the key player in the global nanobodies market. Moreover, the company is developing various products with leading biology companies such as Novo Nordisk A/S, Merck & Co., Inc., Merck KGaA, AbbVie, Inc., and C.H. Boehringer Sohn AG & Ko. KG.

Nanobodies Market Taxonomy:

The global nanobodies market is segmented on the basis of product type, indication, distribution channel, and region:

By Product Type-

  • Mono-specific
    • Monovalent
    • Multivalent
    • Bi-paratopic
  • Multi-specific

By Indication

  • Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
  • Respiratory Syncytial Virus (RSV) Infection
  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus
  • Oncology
  • Immune?mediated Inflammatory Diseases (IMID)
  • Psoriasis
  • Chronic Kidney Diseases
  • Bone Disorders
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography-

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.
Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.